🌍 Global Action Needed! 🌍 The threat of #AntimicrobialResistance and #Tuberculosis (TB) is growing, but innovative research projects like UNITE4TB are helping to lead the charge in developing new treatments. Under the umbrella of the AMR Accelerator and funded by the Innovative Health Initiative (IHI), UNITE4TB is pushing the boundaries of TB research with cutting-edge clinical trials. Sustainable investment is crucial to continue this life-saving work. Ahead of this year's UN High-Level Meeting on AMR, we join our fellow AMR Accelerator partners in underscoring the urgency of maintaining expertise and capabilities to develop new treatments for AMR, TB, and other infectious diseases. Read more about our efforts in our joint call to action published today in Nature Reviews Drug Discovery 👉 https://lnkd.in/e4-nj_T3 #AMR #TB #GlobalHealth #Innovation #UNGAHLM #WeWontRest UNITE4TB is a #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (now Innovative Health Initiative (IHI)). In partnership with: Radboudumc, London School of Hygiene and Tropical Medicine, U. of London, University of Oxford, Oxford University Clinical Research Unit, Research Center Borstel, Lygature, Lancaster University, UCL, MRC Clinical Trials Unit at UCL, TASK, Libera Università Vita-Salute San Raffaele, Helmholtz Munich, KNCV TB Plus, Critical Path Institute (C-Path), European Lung Foundation, ISPUP | Instituto de Saúde Pública da Universidade do Porto, University of Liverpool, IRD, University of Hamburg, University of California, San Francisco, TB Alliance, FIND, Università degli Studi di Milano, Centre Multidisciplinary Research in Health Science , School of Medicine, University of St Andrews, University of St Andrews, Farmaceutiska fakulteten • Uppsala universitet, Uppsala University, European Respiratory Society, TBnet, GSK, Johnson & Johnson, LMU Munich – Ludwig-Maximilians-Universität München, LMU Klinikum München, EFPIA - European Federation of Pharmaceutical Industries and Associations, German Center for Infection Research
UNITE4TB
Non-profitorganisaties
Utrecht, Utrecht 1.158 volgers
Accelerating the development of new treatment regimens for Tuberculosis
Over ons
Worldwide, Tuberculosis (TB) is one of the top 10 causes of death and a leading cause of death and suffering from a single infectious agent. With 30 partners from 13 countries, UNITE4TB aims to set a new standard for anti-TB regimen development. The Consortium is working to upgrade the current clinical trial methodology and enhance the efficiency with which new regimens are delivered.
- Website
-
https://www.unite4tb.org/
Externe link voor UNITE4TB
- Branche
- Non-profitorganisaties
- Bedrijfsgrootte
- 51 - 200 medewerkers
- Hoofdkantoor
- Utrecht, Utrecht
- Type
- Partnerschap
- Opgericht
- 2021
Locaties
-
Primair
Utrecht, Utrecht 3521 AL, NL
Medewerkers van UNITE4TB
-
Michael Hoelscher
Director, Institute of Infectious Diseases & Tropical Medicine bei Ludwig-Maximilians Universität München
-
Cecile Magis-Escurra MD, PhD
Respiratory disease specialist Radboud University Medical Centre, National consultant clinical tuberculosis NVALT
-
Federico Reali
Senior Modelling Scientist and Project Leader at COSBI
Updates
-
📢 Register now for the next UNITE4TB #webinar: Topic: Expert interview: Management of adverse events in TB care Speaker: Dr Simon Tiberi (GSK) Date: 26 September, 13:00–14:00 CEST Educational aims: - To understand the importance of counseling people with TB on adverse events before starting treatment - To evaluate factors that might increase the risk of adverse events and how to monitor them - To learn how to assess and manage adverse events, and if and when to restart TB drugs - To understand the importance of active TB drug safety monitoring Find out more and register 👉 https://lnkd.in/ep8QmQD7 ISPUP | Instituto de Saúde Pública da Universidade do Porto, European Respiratory Society, Innovative Health Initiative (IHI), AMR Accelerator
-
🚀 Exciting Milestone! UNITE4TB has successfully completed participant recruitment for its DECISION trial. This pivotal Phase 2B study is set to evaluate the safety and efficacy of the novel antibiotic BTZ-043 for drug-sensitive TB. Kudos to our dedicated team and partners for their hard work and commitment to advancing TB treatment. 🌍💊 Learn more about this latest milestone and its potential impact 👉 https://lnkd.in/e3ccJdT9 #YesWeCanEndTB #SaveLives #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). AMR Accelerator, LMU Munich – Ludwig-Maximilians-Universität München, LMU Klinikum München, Michael Hoelscher, EFPIA - European Federation of Pharmaceutical Industries and Associations, German Center for Infection Research
-
Happening soon! Don't forget to join our #webinar today starting at 13:00 (CEST). More info and the link to register below 👇
📢 Registration open for the next UNITE4TB #webinar: Expert interview: an approach to market-shaping and access to TB medicines Date: 27 June, 13:00–14:00 CEST Find out more and register 👉 https://lnkd.in/eHtCUM3Y ISPUP | Instituto de Saúde Pública da Universidade do Porto, European Respiratory Society Innovative Health Initiative (IHI) AMR Accelerator
-
Our latest UNITE4TB Newsletter is out, packed with updates and insights on our ongoing efforts to accelerate the development of new treatment regimens for tuberculosis (TB). Here’s a sneak peek at what’s inside: 🔹 2024 Annual Consortium Meeting & Joint Symposium with ERA4TB: Highlights and key takeaways from this event, emphasizing the importance of collaborative efforts in TB research. 🔹 World TB Day Activities: A look back at our activities to mark this year's awareness day. 🔹 Upcoming UNITE4TB webinar: Join us on 27 June for an in-depth discussion on approaches to market-shaping and access to TB medicines. 🔹 Publications: New publications from the UNITE4TB Consortium 🔗👉 https://lnkd.in/esEEiJjc Subscribe to our newsletter for the latest news and updates (see link in comments) #UNITE4TB #EndTB #Newsletter #SubscribeNow #GlobalHealth #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). Proud partner of the AMR Accelerator.
-
📢 Registration open for the next UNITE4TB #webinar: Expert interview: an approach to market-shaping and access to TB medicines Date: 27 June, 13:00–14:00 CEST Find out more and register 👉 https://lnkd.in/eHtCUM3Y ISPUP | Instituto de Saúde Pública da Universidade do Porto, European Respiratory Society Innovative Health Initiative (IHI) AMR Accelerator
-
The 2024 UNITE4TB Consortium Meeting took place in Uppsala, Sweden on 16-17 May, preceded by our first-ever Joint Symposium with ERA4TB on 15 May. The three days generated many valuable insights and lively scientific discussions, providing attendees with a solid overview of the current status of both projects and our ambitions for the future. Special thanks to our hosts, Uppsala University! We're happy to share our post-event summary, with a selection of images from all three days 👉 https://lnkd.in/eCy5Adfj #YesWeCanEndTB #SaveLives #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). Proud partner of the AMR Accelerator. Radboudumc, London School of Hygiene and Tropical Medicine, U. of London, University of Oxford, Oxford University Clinical Research Unit, Research Center Borstel, Lygature, Lancaster University, UCL, MRC Clinical Trials Unit at UCL, TASK, Libera Università Vita-Salute San Raffaele, Helmholtz Munich, KNCV TB Plus, Critical Path Institute (C-Path), European Lung Foundation, ISPUP | Instituto de Saúde Pública da Universidade do Porto, University of Liverpool, IRD, University of Hamburg, University of California, San Francisco, TB Alliance, FIND, Università degli Studi di Milano, Centre Multidisciplinary Research in Health Science , School of Medicine, University of St Andrews, University of St Andrews, Farmaceutiska fakulteten • Uppsala universitet, European Respiratory Society, TBnet, GSK, Johnson & Johnson, Ludwig-Maximilians-Universität München, LMU Klinikum München, EFPIA - European Federation of Pharmaceutical Industries and Associations, German Center for Infection Research
-
📢 Two recent publications coming out of the UNITE4TB Consortium: 1. Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles Source: The Lancet, Microbe 👉 https://lnkd.in/e-zeujXQ "A big effort by the UNITE4TB biomarker team, which will aid future early- and late-stage drug trials and ultimately enable shorter, faster trials with biomarker endpoints," said contributing author and Consortium member, Morten Ruhwald, MD, PhD, Director of TB Programme at FIND. School of Medicine, University of St Andrews, Radboudumc, Ludwig-Maximilians-Universität München, LMU Klinikum München, FIND, German Center for Infection Research, Research Center Borstel, Johnson & Johnson, University of Oxford, Oxford University Clinical Research Unit. 2. Towards comprehensive clinical trials for new tuberculosis drug regimens: policy recommendations from a stakeholder analysis Source: BMJ Global Health, Volume 9, Issue 4 👉 https://lnkd.in/ekHiNyRg This study was carried out by the Centre Multidisciplinary Research in Health Science team at the Università degli Studi di Milano, part of the UNITE4TB Consortium. It discusses #tuberculosis (TB) research and development and the gaps that exist in terms of access to emerging #TB innovations in low- and middle-income countries with high TB burden. #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). AMR Accelerator.
-
That’s a wrap for the 2024 UNITE4TB Annual Meeting, kindly hosted by our Consortium Partner Uppsala University. Closing the meeting, UNITE4TB project lead Derek Sloan (Radboudumc) thanked everyone for their participation and contributions and noted that it’s inspiring and reassuring to see how we are moving forward: "The symposium with ERA4TB provided thought-provoking scientific discussions with a true spirit of joint engagement. UNITE4TB is continuing to build its engine. Our challenge in the coming years is to fully construct this engine and to keep working in a balanced way that makes full use of the multi-disciplinary skillset of the consortium. We will strive to move forward better together." #YesWeCanEndTB #SaveLives #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). Proud partner of the AMR Accelerator.
-
Day 2 of the 2024 UNITE4TB Annual Meeting begins. Today, Tek-Ang Lim (Scientific Officer, Innovative Health Initiative (IHI)) gives a run-down of the IHI Interim Review for UNITE4TB and we hear from our Advisory Boards (Scientific, Ethics, and Community Boards) as well as our Young Investigators Group. We also have a panel discussion about responding to the emerging threat of bedaquiline resistance moderated by Christoph Lange (Research Center Borstel) with speakers from TASK (Caryn Upton), Institute of Tropical Medicine Antwerp (Bouke de Jong), The Janssen Pharmaceutical Companies of Johnson & Johnson (Vivian Cox), and the TB Unit Lead of the World Health Organization Regional Office for Europe (Askar Yedilbayev). Lots to come. It’s sure to be a good one! #PublicPrivatePartnership #YesWeCanEndTB EFPIA - European Federation of Pharmaceutical Industries and Associations; German Center for Infection Research; Ludwig-Maximilians-Universität München; LMU Klinikum München; AMR Accelerator, Uppsala University, Farmaceutiska fakulteten • Uppsala universitet